Meyka Pro banner
23andMe Holding Co.

23andMe Holding Co. Fundamental Analysis (NASDAQ: ME)

ME●NASDAQ
HealthcareMedical - Diagnostics & Research
$0.61
$0.00(0.00%)
U.S. Market opens in 11h 27m

23andMe Holding Co. Fundamental Analysis (NASDAQ: ME)

23andMe Holding Co. (NASDAQ: ME) shows weak financial fundamentals with a PE ratio of -0.06, profit margin of -1.48%, and ROE of -3.47%. The company generates $0.2B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position244.35%
PEG Ratio-0.00

Areas of Concern

ROE-3.47%
Operating Margin-1.27%
Current Ratio0.83
We analyze ME's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -523.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-523.4/100

We analyze ME's fundamental strength across five key dimensions:

Efficiency Score

Weak

ME struggles to generate sufficient returns from assets.

ROA > 10%
-1.76%

Valuation Score

Excellent

ME trades at attractive valuation levels.

PE < 25
-0.06
PEG Ratio < 2
-0.00

Growth Score

Weak

ME faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

ME shows balanced financial health with some risks.

Debt/Equity < 1
-2.56
Current Ratio > 1
0.83

Profitability Score

Weak

ME struggles to sustain strong margins.

ROE > 15%
-347.25%
Net Margin ≥ 15%
-1.48%
Positive Free Cash Flow
No

Key Financial Metrics

Is ME Expensive or Cheap?

P/E Ratio

ME trades at -0.06 times earnings. This suggests potential undervaluation.

-0.06

PEG Ratio

When adjusting for growth, ME's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values 23andMe Holding Co. at -0.59 times its book value. This may indicate undervaluation.

-0.59

EV/EBITDA

Enterprise value stands at 0.10 times EBITDA. This is generally considered low.

0.10

How Well Does ME Make Money?

Net Profit Margin

For every $100 in sales, 23andMe Holding Co. keeps $-1.48 as profit after all expenses.

-1.48%

Operating Margin

Core operations generate -1.27 in profit for every $100 in revenue, before interest and taxes.

-1.27%

ROE

Management delivers $-3.47 in profit for every $100 of shareholder equity.

-3.47%

ROA

23andMe Holding Co. generates $-1.76 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.76%

Following the Money - Real Cash Generation

Operating Cash Flow

23andMe Holding Co. generates limited operating cash flow of $-165.85M, signaling weaker underlying cash strength.

$-165.85M

Free Cash Flow

23andMe Holding Co. generates weak or negative free cash flow of $-172.56M, restricting financial flexibility.

$-172.56M

FCF Per Share

Each share generates $-6.83 in free cash annually.

$-6.83

FCF Yield

ME converts -11.53% of its market value into free cash.

-11.53%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.06

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.59

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.08

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-2.56

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.83

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-3.47

vs 25 benchmark

ROA

Return on assets percentage

-1.76

vs 25 benchmark

ROCE

Return on capital employed

-6.65

vs 25 benchmark

How ME Stacks Against Its Sector Peers

MetricME ValueSector AveragePerformance
P/E Ratio-0.0630.47 Better (Cheaper)
ROE-347.25%556.00% Weak
Net Margin-147.92%32186.00% Weak
Debt/Equity-2.560.52 Strong (Low Leverage)
Current Ratio0.835.83 Weak Liquidity
ROA-175.67%46.00% Weak

ME outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews 23andMe Holding Co.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ